INTERVENTIONAL NEURORADIOLOGY

Testing flow diversion in animal models: a systematic review

Robert Fahed¹ \cdot Jean Raymond^{1,2} \cdot Célina Ducroux¹ \cdot Jean-Christophe Gentric^{2,3} \cdot Igor Salazkin¹ · Daniela Ziegler⁴ · Guylaine Gevry¹ · Tim E. Darsaut⁵

Received: 16 October 2015 /Accepted: 16 December 2015 /Published online: 8 January 2016 \oslash Springer-Verlag Berlin Heidelberg 2016

Abstract

Introduction Flow diversion (FD) is increasingly used to treat intracranial aneurysms. We sought to systematically review published studies to assess the quality of reporting and summarize the results of FD in various animal models.

Methods Databases were searched to retrieve all animal studies on FD from 2000 to 2015. Extracted data included species and aneurysm models, aneurysm and neck dimensions, type of flow diverter, occlusion rates, and complications. Articles were evaluated using a checklist derived from the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.

Electronic supplementary material The online version of this article (doi[:10.1007/s00234-015-1635-0](http://dx.doi.org/10.1007/s00234-015-1635-0)) contains supplementary material, which is available to authorized users.

 \boxtimes Jean Raymond jean.raymond@umontreal.ca

- ¹ Centre Hospitalier de l'Université de Montréal (CHUM), Research Centre, Interventional Neuroradiology Laboratory, Montreal, Quebec, Canada
- ² Centre Hospitalier de l'Université de Montréal (CHUM), Notre-Dame Hospital, Department of Radiology, 1560 Sherbrooke East, Pavilion Simard, Suite Z12909, Montreal, Quebec, Canada H2L 4M1
- ³ Groupe d'étude de la Thrombose en Bretagne Occidentale (GETBO, EA 3878), Brest, France
- ⁴ Centre Hospitalier de l'Université de Montréal (CHUM), Direction de l'Enseignement et de l'Académie CHUM|Bibliothèque, Montreal, Quebec, Canada
- ⁵ Department of Surgery, Division of Neurosurgery, University of Alberta Hospital, Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada

Results Forty-two articles reporting the results of FD in nine different aneurysm models were included. The rabbit elastaseinduced aneurysm model was the most commonly used, with 3-month occlusion rates of 73.5 %, (95 %CI [61.9–82.6 %]). FD of surgical sidewall aneurysms, constructed in rabbits or canines, resulted in high occlusion rates (100 % [65.5– 100 %]). FD resulted in modest occlusion rates (15.4 % $[8.9–25.1 \degree\%]$ when tested in six complex canine aneurysm models designed to reproduce more difficult clinical contexts (large necks, bifurcation, or fusiform aneurysms). Adverse events, including branch occlusion, were rarely reported. There were no hemorrhagic complications. Articles complied with 20.8 ± 3.9 of 41 ARRIVE items; only a small number used randomization (3/42 articles [7.1 %]) or a control group (13/42 articles [30.9 %]).

Conclusion Preclinical studies on FD have shown various results. Occlusion of elastase-induced aneurysms was common after FD. The model is not challenging but standardized in many laboratories. Failures of FD can be reproduced in less standardized but more challenging surgical canine constructions. The quality of reporting could be improved.

Keywords Flow diverter . Animal model . Experimental aneurysm . Systematic review

Introduction

The idea that stents placed in arteries bearing an aneurysm could reduce blood flow in the sac to induce aneurismal thrombosis is at least 20 years old [[1,](#page-6-0) [2\]](#page-6-0), but flexible devices capable of safely reaching intracranial arteries have only recently been developed and approved for clinical use in 2007 [\[3](#page-6-0)] and 2011 [\[4\]](#page-7-0). The clinical introduction of new devices, especially those that change treatment paradigms (for flow

diversion (FD), from occluding the aneurysm sac to repairing the parent vessel), is typically preceded by positive animal studies. FD is a promising and innovative treatment strategy, but unexpected complications and failures have occurred in early clinical series [[5](#page-7-0)–[7](#page-7-0)]. There is little agreement regarding indications, and the exact role FD should play in practice remains unclear [[8](#page-7-0)]. A re-appraisal of the animal studies performed to date may be warranted in order to better understand possible reasons for failures or complications. Multiple preclinical studies, featuring different flow diverters with various aneurysm models have now been published and results vary widely (references available in online supplement). We sought to systematically review the preclinical animal studies to summarize the results and attempt to identify reasons for discrepancies. A second goal was to assess whether preclinical studies realistically anticipated clinical results. Finally, we aimed to assess the quality of reporting using a checklist derived from the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines [\[9](#page-7-0)].

Materials and methods

Search strategy

The systematic review was performed according to the guidelines [[10](#page-7-0)–[12](#page-7-0)]. Search strategies were developed using terms from controlled vocabularies (MeSH for MEDLINE, EMTREE for EMBASE, and CINAHL Headings). We used words from "all fields" for Cochrane Central and from "title" and "abstract" to identify studies in MEDLINE, EMBASE, and CINAHL. The search interfaces were PubMed for MEDLINE, Ovid for MEDLINE, EMBASE and Cochrane, and EBSCO for CINAHL. Details of the search strategy are provided in the Appendix. We also hand-searched grey literature sources, including: System for Information on Grey Literature in Europe (Open Grey), National Guideline Clearing House, National Institutes for Health and Clinical Excellence (NICE), The Grey Literature Report (NYAM), Google, and Google Scholar.

We included all articles that met the following selection criteria: (1) an animal study; (2) at least one flow diverter used; (3) peer-reviewed; (4) original research (review articles, abstracts, editorials, and letters excluded); (5) English or French language.

The data extraction form is available in the supplemental material (online). Extracted data included: (i) study characteristics: (year of publication, laboratory, funding source (industry, public, both or unclear), and number of citations; (ii) animal

Data extraction

and presence of jailed branches; (iii) type of flow diverter; (iv) treatment (single or multiple devices, anti-platelet medications); (v) results: method of angiography, timing of followup studies, aneurysm occlusion rates, incidence of parent or jailed branch vessel stenosis or occlusion; and pathology. Successful FD was predefined as complete or near-complete occlusion of the aneurysm.

To assess the quality of reporting, we used a checklist derived from the 38 ARRIVE guidelines [[9\]](#page-7-0). Three items were added for a total of 41 items: (i) the use of a control group, (ii) the use of an explicit definition of aneurysm occlusion, and (iii) the mention of the method of selection of the size of the device. Data extraction was performed by two independent authors (RF and CD), and discrepancies were reviewed through consensus. Differences in experimental methods, animal models, species, devices, outcome measures, follow-up periods, and definitions of angiographic occlusion were considered in the judgment of whether numerical results could be combined into a meta-analysis.

Results

The initial title search yielded 3544 publications (Fig. [1\)](#page-2-0). After viewing the abstracts, 3462 articles were excluded, retaining 82 articles for full text evaluation; 40 articles were excluded because they did not meet the selection criteria, leaving 42 articles for final analyses (references available in online supplement).

The first paper on FD in laboratory animals was published in 2003; 11 were published between 2003 and 2009; 31 (or 74 %) between 2010 and 2015. Studies were conducted in 9 laboratories, 3 in North America (27 publications), 3 in Asia (10 publications), and 3 in Europe (5 publications).

Eighteen articles (40.9 %) were published in two journals (AJNR and Neuroradiology). The median (interquartile range (IQR)) number of citations (according to [[http://scholar.google.](http://scholar.google.ca) [ca\]](http://scholar.google.ca)—search performed on August 11, 2015) was 12 (5–18). Three articles presenting the first preclinical results of FD in the rabbit elastase-induced model had more than 100 citations.

Twenty-eight (67 %) studies were at least partially funded by public institutions; seven studies (17 %) were solely funded by industry. Funding sources could not clearly be identified in seven articles (17 %).

Quality of reporting

Overall, articles complied with 20.8 ± 3.9 ARRIVE items, with a range of $12-28/41$. Five articles included more than 25 of 41 items; 21 articles complied with 20–25 items; 16 articles included less than 20 items. Main results are presented in Fig. [2](#page-2-0) (details can be found in Fig. [3\)](#page-3-0). The median number of items was 23 (22–24) in canine studies; 20 (17–22) in rabbit

Fig. 1 Flow-chart

studies. The median number of items reported in the seven industry-funded studies was 20 (18.5–20.5) versus 22 (18– 23.5) in the remaining 35 studies.

The items that were most commonly reported were provision of a scientific background, details of how the procedure was carried out, and interpretation of results. Other items, such as mode of treatment allocation (7/42,

16.7 %) and details of adverse events (13/42, 30.9 %) were less commonly reported.

A justification for the choice of the size of the device was mentioned in 14/42 (33.3 %) articles. None of the 42 articles mentioned the ARRIVE guidelines for reporting animal studies.

Aneurysm models

Two species were used: rabbits (29) and canines (13 articles). None of the articles tested FD in both species.

There were nine different aneurysm models. The rabbit-elastase model was used in 25 articles (440 aneurysms), by eight of nine laboratories. The surgical sidewall carotid model was the next most frequently used, with two laboratories, six articles, 67 aneurysms in canines, and one laboratory, one article, 22 aneurysms in rabbits. Six complex canine models were reported in seven articles, including a curved sidewall (two articles, nine aneurysms), an end-wall bifurcation (two articles, 23 aneurysms), a Y-bifurcation (one article, 20 aneurysms), and a giant fusiform aneurysm model (one article, six aneurysms). Mean aneurysm dimensions for the various models are presented in Table [1](#page-3-0).

Articles reported a mean of 17.7 ± 8.5 rabbits per study (elastase model); studies on canine models reported 11.2 ± 6.2 animals per article. Published operative mortality rates were 1.4 % (95 %CI [0.6–2.9 %]) in the rabbit studies and 3.4 % (95 %CI $[0.1–6.7 \text{ %}0]$) in the canine studies. Most aneurysms were reported to be patent at the time of treatment (462/462 rabbit aneurysms; 165/168 canine aneurysms).

Fig. 3 Compliance with ARRIVE guidelines

Flow diverters

The PED was most frequently studied, but only in rabbits (153 devices in 153 rabbit aneurysms). The FRED device was mostly used in canine aneurysms (137 devices; 115 devices

in 85 canine aneurysms). Twelve different devices were tested in the rabbit-elastase model. Most studies (39/42, 92.8 %) used a single flow diverter (in 476 aneurysms), while multiple telescoping devices were studied in 3 articles (65 devices to treat 26 aneurysms). Two articles assessed intra-saccular FD

Mean aneurysm dimensions (mm)

Table 1 Aneurysm models

(a Some canine studies involved several aneurysm models)

(36 devices in 36 rabbit elastase-induced aneurysms). Details about the number of articles assessing each device are available in Table 2.

Results of flow diversion

Aneurysm occlusion was studied in 39/42 articles (92.8 %); the three remaining articles focused on the patency of jailed branches. An explicit definition of aneurysm occlusion was reported in 21/39 (53.8 %) articles, with the scale of Kamran et al. [\[13](#page-7-0)] most commonly used (eight articles). Eight other articles (19 %) used a 3-point occlusion scale (complete/nearcomplete/incomplete occlusion).

Intra-arterial catheter angiography was used to assess results of FD in 32/39 articles (82 %). Intravenous angiography was used in 4/39 articles (10.2 %). The occlusion of aneurysms was only verified at pathology in 4/39 articles (10.2 %).

A comparator or control group was reported in 13/39 (33.3 %) articles (nine canine studies and four rabbit studies): 7/39 (17.9 %) studies included aneurysms treated with non-FD devices; 3/39 (7.7 %) included untreated control aneurysms, and 3/39 articles (7.7 %) involved both types of controls.

The various experimental methods and models, species, devices, outcome measures, follow-up periods, and definitions of angiographic occlusion were too heterogeneous to allow meta-analysis.

Aneurysm occlusion was most commonly assessed at 3 months (20/39 articles [51.3 %]). Results are summarized in Table 3. Details are provided in Table [4.](#page-5-0)

Table 2 Details of FDs used in each species

Device	Number of aneurysms treated $(Total = 502$ aneurysms)	
	Rabbit aneurysms	Canine aneurysms
Intraluminal FD		
PED	153 (28.7 %)	θ
FRED	$22(4.1\%)$	$85(16.0\%)$
Tubridge	49 (9.8 %)	Ω
Surpass	$30(5.6\%)$	Ω
Silk	$12(2.2\%)$	θ
Asymmetric vascular stent (AVS)	$26(5.2\%)$	$10(1.9\%)$
Microporous stentgraft	$10(1.9\%)$	33 $(6.2\%$
Undetermined/other	33 $(6.2\%$	$3(0.6\%)$
Intrasaccular FD		
Web	$24(4.5\%)$	θ
Luna	$12(2.2\%)$	θ
Total	371 (73.9 %)	131 (26.1%)

Table 3 Summary of aneurysm occlusion rates at 3 months

Three months after FD, rabbit elastase-induced aneurysms were completely or near-completely occluded in 50/68 cases (73.5 %, 95 %CI [61.9–82.6 %]); surgical sidewall aneurysms were completely and near-completely occluded in 9/9 cases $(100 \text{ %}; [65.5–100 \text{ %}]).$ Canine complex aneurysms were completely and near-completely occluded in 12/78 cases $(15.4 \%, [8.9-25.1 \%])$.

All seven industry-funded studies involved rabbits: five used the rabbit elastase-induced model, one used the rabbit surgical sidewall model, and one study focused on the patency of jailed branches after device implantation in the abdominal aorta. The overall rate of (near)-complete occlusion of the industry-funded studies was 98/105 aneurysms (93.3 %, $[86.6-97.0 \%]$.

Anti-platelet regimen

Details regarding the anti-platelet regimen were available in 35/42 (83.3 %) of articles. ASA and clopidogrel were used in 25 articles, a single anti-platelet agent in five articles. Antiplatelet agents were not administered in four studies.

Complications

Five articles reported seven parent artery occlusions visible on follow-up angiograms. In two articles (four parent artery occlusions), the authors proposed that complications were due to a failure to fully deploy the devices.

There was a single reported branch occlusion (out of 18 articles) in which retrograde flow in a jailed right vertebral artery was noted.

Because none of the articles reported a denominator (the number of arteries or branches that could have become

Table 4 Summary of aneurysm occlusion rates

occluded after flow diversion), a rate of arterial or branch occlusion could not be extracted in this review.

Parent artery stenosis was assessed in 22/42 articles (52.4 %) (eight canine and 14 rabbit studies). Among the 22 studies, at least one parent vessel stenosis was noted in 5/8 canine studies (62.5 %) and $3/14$ rabbit studies (21.4 %). Because of suboptimal reporting and heterogeneity, a rate of parent artery stenosis could not be extracted from this data.

No hemorrhagic complications from FD were reported in any article.

Pathological analyses

Pathological results were reported in 31/42 (73.8 %) of articles. Most common findings were that treated aneurysms were partially or completely filled with organized connective tissue (18 articles; seven canine and 11 rabbit studies), and partial or complete neointimal coverage of the device overlying the aneurysm ostium was found (19 articles; six canine and 13 rabbit studies).

Discussion

The main findings of this review are (1) almost all laboratories used a standardized rabbit-elastase model, featuring small aneurysms with a narrow neck, to test 12 different devices. Occlusion rates were high at all time points with most devices; (2) fewer laboratories used surgical sidewall aneurysms; only three devices were tested in rabbits and canines, with high occlusion rates; (3) more complex canine models were used to test FD in contexts of treatment failure (large or giant widenecked aneurysms at bifurcations for example), with modest occlusion rates (approximately 15 %); (4) branch or parent vessel occlusion has rarely been reported, and none of the hemorrhagic complications reported in humans treated with FD have been described in animals; (5) reporting of animal studies could benefit from compliance with the ARRIVE guidelines.

The capacity for animal studies to predict the clinical efficacy of innovative treatments has been questioned, particularly after the disappointing results of clinical trials on neuroprotective agents shown effective in preclinical studies [\[14](#page-7-0)–[16\]](#page-7-0). There are many reasons for the discrepancies between animal and clinical results. One surmountable problem is the lack of transparent reporting of study design and implementation [[14,](#page-7-0) [17\]](#page-7-0). Recent studies have shown that 80 % of reported animal studies do not describe key aspects of study design, such as randomization or method of blinding [\[17,](#page-7-0) [18\]](#page-7-0). In one survey, important adverse events in animals were reported in less than 10 % of publications [[19](#page-7-0)]. Inadequate reporting may reduce the credibility of preclinical studies and act as barriers to successful translation of research findings. The ARRIVE guidelines were developed to promote consistency in reporting of animal studies [[9\]](#page-7-0). They have been endorsed by the US National Research Council Institute for Laboratory Animal Research [[20,](#page-7-0) [21\]](#page-7-0). The present review suggests that the design and reporting of animal studies on FD could be improved if investigators complied with available guidelines. Items that can substantially influence results, such as randomization, blinding, or justification of sample size, were infrequently used or reported.

Another barrier to the reliability of preclinical reviews is the presence of publication bias [\[22](#page-7-0), [23](#page-7-0)]. The predominance of positive studies for various devices in terms of aneurysm occlusion and safety, and the low mortality and spontaneous aneurysm occlusion rates suggest the present review may be affected by publication bias.

Most devices were studied in a generally practiced, apparently standardized rabbit elastase aneurysm model. The severity of the testing accomplished with this model may be questioned when one considers the variety of treatment strategies (including coiling or second-generation coiling [\[24](#page-7-0), [25\]](#page-7-0), and high-porosity stenting [[26,](#page-7-0) [27\]](#page-7-0)) previously shown successful and the high occlusion rates reported in the present review. Yet, the overall occlusion rates obtained with FD in the rabbit model is in line with human results reported in systematic reviews of clinical case series [\[28](#page-7-0)].

Similar considerations apply to the ability of preclinical testing to anticipate clinical complications. While the parenchymal hematomas and the delayed aneurysmal ruptures that occasionally follow clinical applications of FD [\[5,](#page-7-0) [7,](#page-7-0) [29\]](#page-7-0) were never reported in animal models (except in a small explanatory study that did not specifically used flow diverters [[30](#page-7-0)]), the reassuring paucity of thrombotic complications seems to have correctly anticipated the relatively small number of ischemic complications encountered in human applications [[6](#page-7-0), [28\]](#page-7-0). It is important to remember that few studies looking at arterial patency rates in a small number of animals at fixed time points (which could miss occluded arteries that subsequently recanalized) should not be expected to anticipate clinical complications that could follow even a transient occlusion of a human perforating artery.

Results of FD were heterogeneous. The wide discrepancies between occlusions reported in rabbit models (and sidewall canine aneurysms) and failures reported in other canine models can readily be explained by differences in the configuration of the parent vessel-aneurysm complex (such as surgically created bifurcations), parent artery sizes and flow rates, aneurysm dimensions, in addition to biological differences between species. Thus, a meta-analysis of all results obtained with the various models combined to estimate the overall success of FD, in an attempt to anticipate results in human applications, would not make sense. The more severe testing that can be achieved with some surgical canine models was not designed to match a clinical occlusion rate, but to investigate potential causes for failures which can occur when FD is used in challenging clinical contexts [[31\]](#page-7-0).

For the same reasons, comparing occlusion rates for various devices in different studies is inappropriate. One must ensure that the same aneurysm model, aneurysm and neck sizes, methodology, time points, and occlusion scales have been used. Ideally, valid comparisons would necessitate a specific experimental design, with blinded adjudication of angiographic outcomes, comparing animals randomly allocated to one device or another.

Various animal models may play different roles. The most frequently used rabbit elastase-induced aneurysm model features small aneurysms that do not severely test the device under examination. It is a standardized model, available in multiple laboratories, that seems to be a good starting point. Failures observed in this relatively easy model may signify that the device being tested needs further improvements.

Some surgical constructions in canines have the capacity to place FD into circumstances where aneurysm occlusion can be a challenge. However, these models have not been replicated and standardized, and they may require a surgical expertise that is not readily available in all laboratories.

Limitations

We included only studies published in English or French, and some publications may have been missed. Positive studies are more likely to be published in English, and the review may suffer from language bias [\[32\]](#page-7-0). We did not perform a metaanalysis because of the substantial heterogeneity in methods and results. One important source of heterogeneity, whose impact on treatment results and complications remains unclear, is the differences in biology and response to antiplatelet agents between animals of the same species as well as between different species.

Conclusion

Preclinical studies on FD have shown various results. Occlusion of elastase-induced aneurysms was common after FD. The model is not challenging but standardized in many laboratories. Failures of FD can be reproduced in less standardized but more challenging surgical canine constructions. Quality of reporting could be improved.

Acknowledgments RF receives a research scholarship from the Fondation pour la Recherche Médicale (FRM), Paris, FRANCE (grant number DEA20140630151). Tim Darsaut received a research grant from the Heart and Stroke Foundation of Alberta (grant # GIA-0200296).

Compliance with ethical standards We declare that this manuscript does not contain clinical studies or patient data

Conflict of interest We declare that we have no conflict of interest.

References

- 1. Turjman F, Acevedo G, Moll T, Duquesnel J, Eloy R, Sindou M (1993) Treatment of experimental carotid aneurysms by endoprosthesis implantation: preliminary report. Neurol Res 15: 181–184
- 2. Geremia G, Haklin M, Brennecke L (1994) Embolization of experimentally created aneurysms with intravascular stent devices. AJNR Am J Neuroradiol 15:1223–1231
- 3. Byrne JV, Beltechi R, Yarnold JA, Birks J, Kamran M (2010) Early experience in the treatment of intra-cranial aneurysms by endovascular flow diversion: a multicentre prospective study. PLoS One 5:e12492. doi:[10.1371/journal.pone.0012492](http://dx.doi.org/10.1371/journal.pone.0012492)
- 4. U.S. Food and Drug Administration. Pipeline™ Embolization Device-P100018. USA: 2011/04/06; [http://www.hc-sc.gc.ca/dhp](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/md-im/sbd_smd_2010_pipeline_embolization_148227-eng.php)[mps/prodpharma/sbd-smd/md-im/sbd_smd_2010_pipeline_](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/md-im/sbd_smd_2010_pipeline_embolization_148227-eng.php) [embolization_148227-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/md-im/sbd_smd_2010_pipeline_embolization_148227-eng.php). [http://www.fda.gov/](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm252130.htm) [MedicalDevices/ProductsandMedicalProcedures/](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm252130.htm) [DeviceApprovalsandClearances/Recently-ApprovedDevices/](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm252130.htm) [ucm252130.htm](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm252130.htm)
- 5. Kulcsar Z, Houdart E, Bonafe A, Parker G, Millar J, Goddard AJ, Renowden S, Gál G, Turowski B, Mitchell K, Gray F, Rodriguez M, van den Berg R, Gruber A, Desal H, Wanke I, Rüfenacht DA (2011) Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. AJNR Am J Neuroradiol 32:20–25. doi[:10.3174/ajnr.A2370](http://dx.doi.org/10.3174/ajnr.A2370)
- 6. Kulcsar Z, Ernemann U, Wetzel SG, Bock A, Goericke S, Panagiotopoulos V, Forsting M, Ruefenacht DA, Wanke I (2010) High-profile flow diverter (SILK) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforators. Stroke 41:1690–1696. doi[:10.1161/STROKEAHA.110.580308](http://dx.doi.org/10.1161/STROKEAHA.110.580308)
- 7. Turowski B, Macht S, Kulcsar Z, Hänggi D, Stummer W (2011) Early fatal hemorrhage after endovascular cerebral aneurysm treatment with a flow diverter (SILK-Stent): do we need to rethink our concepts? Neuroradiology 53:37–41. doi:[10.1007/s00234-010-0676-7](http://dx.doi.org/10.1007/s00234-010-0676-7)
- Darsaut TE, Gentric JC, McDougall CM, Gevry G, Roy D, Weill A, Raymond J (2015) Uncertainty and agreement regarding the role of flow diversion in the management of difficult aneurysms. AJNR Am J Neuroradiol 36:930–936. doi[:10.3174/ajnr.A4201](http://dx.doi.org/10.3174/ajnr.A4201)
- 9. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412. doi[:10.1371/journal.pbio.1000412](http://dx.doi.org/10.1371/journal.pbio.1000412)
- 10. Higgins J, Green S Cochrane handbook for systematic reviews of interventions. Version 5.1.0. (updated March 2011) [http://](http://handbook.cochrane.org/) handbook.cochrane.org/
- 11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008–2012
- 12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 6:e1000097. doi:[10.](http://dx.doi.org/10.1371/journal.pmed.1000097) [1371/journal.pmed.1000097](http://dx.doi.org/10.1371/journal.pmed.1000097)
- 13. Kamran M, Yarnold J, Grunwald IQ, Byrne JV (2011) Assessment of angiographic outcomes after flow diversion treatment of intracranial aneurysms: a new grading schema. Neuroradiology 53:501– 508. doi[:10.1007/s00234-010-0767-5](http://dx.doi.org/10.1007/s00234-010-0767-5)
- 14. Cumberland Consensus Working Group, Cheeran B, Cohen L, Dobkin B, Ford G, Greenwood R, Howard D, Husain M, Macleod M, Nudo R, Rothwell J, Rudd A, Teo J, Ward N, Wolf S (2009) The future of restorative neurosciences in stroke: driving the translational research pipeline from basic science to rehabilitation of people after stroke. Neurorehabil Neural Repair 23:97–107. doi[:10.1177/1545968308326636](http://dx.doi.org/10.1177/1545968308326636)
- 15. Kaste M (2005) Use of animal models has not contributed to development of acute stroke therapies: pro. Stroke 36:2323–2324
- 16. Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I, Reviewing Animal Trials Systematically (RATS) Group (2004) Where is the evidence that animal research benefits humans? BMJ 328:514–517
- 17. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, Hutton J, Altman DG (2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4:e7824. doi:[10.1371/journal.pone.0007824](http://dx.doi.org/10.1371/journal.pone.0007824)
- 18. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S, Macleod MR (2010) Improving the translational hit

of experimental treatments in multiple sclerosis. Mult Scler 16: 1044–1055. doi[:10.1177/1352458510379612](http://dx.doi.org/10.1177/1352458510379612)

- 19. Ting KH, Hill CL, Whittle SL (2015) Quality of reporting of interventional animal studies in rheumatology: a systematic review using the ARRIVE guidelines. Int J Rheum Dis 18:488–494. doi: [10.1111/1756-185X.12699](http://dx.doi.org/10.1111/1756-185X.12699)
- 20. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187–191. doi[:10.1038/nature11556](http://dx.doi.org/10.1038/nature11556)
- 21. National Research Council Institute for Laboratory Animal Research (2011) Guidance for the description of animal research in scientific publications. Washington (District of Columbia). National Academies Press. Available online [http://www.nap.edu/](http://www.nap.edu/openbook.php?record_id=13241) [openbook.php?record_id=13241](http://www.nap.edu/openbook.php?record_id=13241)
- 22. Sena ES, van der Worp HB, Bath PM et al (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8:e1000344. doi[:10.1371/journal.pbio.1000344](http://dx.doi.org/10.1371/journal.pbio.1000344)
- 23. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR (2010) Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab 30:1905–1913. doi[:10.1371/journal.pbio.1000344](http://dx.doi.org/10.1371/journal.pbio.1000344)
- 24. Kallmes DF, Helm GA, Hudson SB, Altes TA, Do HM, Mandell JW, Cloft HJ (1999) Histologic evaluation of platinum coil embolization in an aneurysm model in rabbits. Radiology 213:217–222
- 25. Ding YH, Dai D, Lewis DA, Cloft HJ, Kallmes DF (2005) Angiographic and histologic analysis of experimental aneurysms embolized with platinum coils, Matrix, and HydroCoil. AJNR Am J Neuroradiol 26:1757–1763
- 26. Hans FJ, Krings T, Moller-Hartmann W, Thiex R, Pfeffer J, Scherer K, Brunn A, Dreeskamp H, Stein KP, Meetz A, Gilsbach JM, Thron A (2003) Endovascular treatment of experimentally induced aneurysms in rabbits using stents: a feasibility study. Neuroradiology 45:430–434
- 27. Krings T, Hans FJ, Moller-Hartmann W, Brunn A, Thiex R, Schmitz-Rode T, Verken P, Scherer K, Dreeskamp H, Stein KP, Gilsbach J, Thron A (2005) Treatment of experimentally induced aneurysms with stents. Neurosurgery 56:1347–1359, discussion 1360
- 28. Brinjikji W, Murad MH, Lanzino G, Cloft HJ, Kallmes DF (2013) Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 44:442–447. doi:[10.1161/](http://dx.doi.org/10.1161/STROKEAHA.112.678151) [STROKEAHA.112.678151](http://dx.doi.org/10.1161/STROKEAHA.112.678151)
- 29. Cruz JP, Chow M, O'Kelly C, Marotta B, Spears J, Montanera W, Fiorella D, Marotta T (2012) Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms. AJNR Am J Neuroradiol 33:603–608. doi[:10.](http://dx.doi.org/10.3174/ajnr.A3065) [3174/ajnr.A3065](http://dx.doi.org/10.3174/ajnr.A3065)
- 30. Raymond J, Darsaut TE, Kotowski M, Makoyeva A, Gevry G, Berthelet F, Salazkin I (2013) Thrombosis heralding aneurysmal rupture: an exploration of potential mechanisms in a novel giant swine aneurysm model. AJNR Am J Neuroradiol 34:346–353. doi[:10.3174/ajnr.A3407](http://dx.doi.org/10.3174/ajnr.A3407)
- 31. Siddiqui AH, Abla AA, Kan P, Dumont TM, Jahshan S, Britz GW, Hopkins LN, Levy EI (2012) Panacea or problem: flow diverters in the treatment of symptomatic large or giant fusiform vertebrobasilar aneurysms. J Neurosurg 116:1258–1266. doi:[10.3171/2012.2.JNS111942](http://dx.doi.org/10.3171/2012.2.JNS111942)
- 32. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31:115–123